Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial-Reference-Cited by-同舟云学术

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

Published:2009-04-07 Issue:5 Volume:104 Page:1170-1179
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Colombel Jean-Frédéric,Sandborn William J,Rutgeerts Paul,Kamm Michael A,Yu Andrew P,Wu Eric Q,Pollack Paul F,Lomax Kathleen G,Chao Jingdong,Mulani Parvez M

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg200959.pdf

Reference8 articles.

1. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

2. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease

3. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

4. ESTIMABILITY AND ESTIMATION IN CASE-REFERENT STUDIES

5. Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving Landscape of Biologic Therapy for Pediatric Psoriasis;Dermatologic Clinics;2024-07

2. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study;Inflammatory Bowel Diseases;2023-11-10

3. Net Remission Rates with Biologic Treatment in Crohn’s Disease: A Reappraisal of the Clinical Trial Data;Clinical Gastroenterology and Hepatology;2023-05

4. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?;Expert Opinion on Biological Therapy;2023-04-03

5. Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease;European Journal of Gastroenterology & Hepatology;2022-09-12